The administration of US President Donald Trump announced during a press conference, requesting millions of units of "chloroquine and hydroxychloroquine" that are used in the treatment of malaria, among other drugs, to be tested as a possible treatment for Corona virus, and it is not the first time that these drugs are mentioned as possible treatments for viral disease.

As the early test for hydroxychloroquine in France showed promising results, and the results indicated that 50% of patients who had been infected with the virus were negative, after only three days of treatment, according to the "Arabia" website.

Hydroxycholorquine (sold under the brand name Plaquenil), and its closely related chloroquine, were certified in 1950 mainly as anti-malarial therapies. Since then, medications have been used for a wide range of diseases, including systemic lupus erythematosus (known as "lupus"), rheumatoid arthritis, Sjogren's syndrome, and even for complications of Lyme disease.

These drugs act at the molecular level to disrupt critical cell processes, which disrupts the body's immune response.

Since the normal immune response is responsible for inflammation and other symptoms of general illness (such as pain, fever, pain, etc.), this anti-immune process reduces systemic diseases such as rheumatoid arthritis.

Although hydroxychloroquine may be effective, it can cause many side effects, including but not limited to headache, loss of appetite, nausea, vomiting, rash, etc. A serious side effect is loss of vision due to retinal toxicity.

There is still a great deal of work to do before announcing these medications as a viable treatment option for Corona, especially regarding long-term efficacy, safety, and patient outcomes.